# US 5,346,686 A · Labelled interleukin-8 and medical uses thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,346,686 A - Document ID: US5346686A - Status: Granted - Kind: A - Application number: 07/956,863 - Filed: 1992-10-05 - Granted: 1994-09-13 - Earliest claimed: 1992-10-05 - Assignees: Mallinckrodt Medical, Inc.; Curators of the University of Michigan - Inventors: Leon R. Lyle; Steven L. Kunkel - Web page: https://patentgrep.com/patent/US5346686A ## CPC - A61K 51/08: Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins} - A61K 2123/00: Preparations for testing in vivo - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract A method of imaging a target site in an animal's body in which a labelled CXC chemokine is introduced into the animal's body and allowed to accumulate at a target site which includes Interleukin-8 receptor molecules. The accumulated, labelled CXC chemokine is then detected so as to image the target site of the body. ## Claims ### Claim 1 A method of imaging a target site in an animal body, comprising providing a radionuclide-labelled CXC chemokine, wherein C stands for cysteine and X stands for an amino acid, introducing a detectable amount of said labelled CXC chemokine into an animal's body, allowing the labelled CXC chemokine to accumlate at a target site of the animal's body, wherein neutrophils having Interleukin-8 receptor molecules are located at said target site, and detecting the accumulated, labelled CXC chemokine so as to image said target site. ### Claim 2 (depends on 1) The method of claim 1 wherein said target site is an inflamed or diseased portion of said animal's body. ### Claim 3 (depends on 1) The method of claim 1 wherein said labelled CXC chemokine is radiolabelled CXC chemokine. ### Claim 4 (depends on 3) The method of claim 3 wherein said CXC chemokine is labelled with indium-111, iodine-123, technetium-99m or copper-62. ### Claim 5 (depends on 4) The method of claim 4 wherein said indium-111 is carried by a lysine of said CXC chemokine. ### Claim 6 (depends on 4) The method of claim 4 wherein said CXC chemokine is labelled with indium-111 utilizing a chelating agent. ### Claim 7 (depends on 6) The method of claim 6 wherein said chelating agent is C-DTPA. ### Claim 8 (depends on 6) The method of claim 6 wherein said CXC chemokine is human Interleukin-8. ### Claim 9 (depends on 4) The method of claim 4 wherein said iodine-123 is carried by a tyrosine, iodophenyl derivative or lysine of said CXC chemokine. ### Claim 10 (depends on 4) The method of claim 4 wherein said CXC chemokine is labelled with iodine-123 utilizing chloramine-T hydrate. ### Claim 11 (depends on 10) The method of claim 10 wherein said CXC chemokine is human Interleukin-8. ### Claim 12 (depends on 4) The method of claim 4 wherein said CXC chemokine is labelled with technetium-99m. ### Claim 13 (depends on 12) The method of claim 12 wherein said technetium-99m is carried by a lysine or an added free cysteine of said CXC chemokine. ### Claim 14 (depends on 1) The method of claim 1 wherein said CXC chemokine is labelled utilizing a chelating agent. ### Claim 15 (depends on 14) The method of claim 14 wherein said chelating agent is a triamide thiolate ligand, a diamide dithiolate ligand or a diamide diphenolic ligand. ### Claim 16 (depends on 15) The method of claim 15 wherein said CXC chemokine is labelled with technetium-99m or copper-62 and said chelating agent is a triamide thiolate ligand. ### Claim 17 (depends on 12) The method of claim 12 wherein said CXC chemokine is human Interleukin-8. ### Claim 18 (depends on 1) The method of claim 1 wherein said CXC chemokine is human Interleukin-8. ### Claim 19 A method of delivering a labeling agent to a target site of an animal's body, comprising introducing into an animal's body a CXC chemokine carrying a radionuclide labeling agent, wherein C stands for cysteine and X stands for an amino acid, and allowing the labeling agent-carrying CXC chemokine to accumulate at a target site, wherein neutrophils having Interleukin-8 receptor molecules are located at said target site, so as to deliver said labeling agent to said target site. ### Claim 20 A method of delivering a radioactive agent to a target site of an animal's body comprising introducing into an animal's body a CXC chemokine carrying a radioactive agent, wherein C stands for cysteine and X stands for an amino acid, and allowing the radioactive agent-carrying CXC chemokine to accumulate at a target site, wherein neutrophils having Interleukin-8 receptor molecules are located at said target site, so as to deliver said radioactive agent to said target site. ### Claim 21 A composition comprising a CXC chemokine carrying a radioactive labeling agent, wherein said radioactive labeling agent is selected from the group consisting of indium-111, and technetium-99m. ### Claim 22 (depends on 21) The composition of claim 21 wherein said CXC chemokine is labelled with said radioactive labeling agent by utilizing a chelating agent which is conjugated to said CXC chemokine. ### Claim 23 (depends on 22) The composition of claim 22 wherein said chelating agent is a triamide thiolate ligand, diamide dithiolate ligand or diamide diphenolic ligand.